Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Search
Ridgefield, CT | BI Facilities
BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
Partnering
Partnering
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
Swine
Swine
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
Promising Phase II Results in Chronic Kidney Disease
Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease
Management Rotation | Academic Programs
Management Rotation Program
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Our Innovation Strategy
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Introducing Ingelvac Provenza™ | Boehringer Ingelheim US
Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.